New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 27, 2013
11:14 EDTCVS, BX, BIOSCVS acquires home infusion provider
CVS Caremark (CVS) has agreed to buy the Coram unit of Apria Healthcare. Coram provides infused and oral medications to patients at their homes. BioScrip (BIOS), which also provides home-based infusion therapies, surged following the deal announcement. WHAT'S NEW: CVS announced earlier that it has agreed to buy Coram from Apria for about $2.1B. Coram specializes in providing infusion therapies, which involves administering medicine via catheter or injection to patients who cannot be treated with oral medicine. Apria is owned by The Blackstone Group (BX). "Bringing together CVS Caremark's unique range of specialty pharmacy services with Coram's infusion capabilities will expand our competitive offerings in the specialty arena," said the president of CVS Caremark Pharmacy Services, Jon Roberts. "Infusion will be a valuable component of our broad specialty pharmacy offering going forward," added Roberts. ANALYST REACTION: CVS' purchase of Coram is a validation of the value of home-based infusion therapies, wrote Jefferies analyst Brian Tanquilut in a note to investors. The deal indicates that home-based infusion providers have strategic value for healthcare providers who want to benefit from the continued increases in spending on specialty drugs, the analyst added. These drugs are increasingly being administered in patients' homes, the analyst added. Based on the price that CVS paid for Coram, BioScrip, which also provides home-based infusion therapies, could realistically be acquired for $12-$14 per share, wrote Tanquilut. However, BioScrip probably won't get sold for at least the next six months, added the analyst, who kept an $11 price target and Buy rating on BioScrip shares. PRICE ACTION: In late morning trading, BioScrip surged $1.18, or 20%, to $7.10, while CVS rose a bit over 1% to $66.80.
News For CVS;BIOS;BX From The Last 14 Days
Check below for free stories on CVS;BIOS;BX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 22, 2014
07:25 EDTCVSNatural E Creative Group to hold a summit
Subscribe for More Information
April 21, 2014
14:24 EDTCVSCVS wants price competition to Gilead's hepatitis C drug, Bloomberg says
CVS said it may try to slow uptake of Gilead's new hepatitis C drug, which costs $1,000 per pill. Bloomberg cites an interview with CVS's CMO Troy Brennan.
11:46 EDTBXStocks with call strike movement; BX GM
Subscribe for More Information
08:06 EDTBXBlackstone outlook has improved, says JMP Securities
JMP Securities believes that Blackstone reported strong Q1 results, and the firm is more upbeat on the company's outlook following the results. The firm thinks the stock is undervalued at current levels and reiterates an Outperform rating on the shares.
April 17, 2014
11:10 EDTBXBlackstone says staying away from 'crowded deals and expensive sectors' in U.S.
Comment from Blackstone's Q1 investor call.
10:11 EDTBXHigh option volume stocks: CMG INFY GOOGL GOOG SNDK MAT YHOO BX KSU GILD
Subscribe for More Information
08:58 EDTBXOn The Fly: Pre-market movers
Subscribe for More Information
07:03 EDTBXBlackstone reports Q1 ENI 70c , consensus 55c
Subscribe for More Information
April 16, 2014
15:17 EDTBXNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include General Electric (GE), consensus 32c; Philip Morris (PM), consensus $1.16; Schlumberger (SLB), consensus $1.20; PepsiCo (PEP), consensus 75c; Union Pacific (UNP), consensus $2.37; UnitedHealth (UNH), consensus $1.09; Honeywell (HON), consensus $1.26; Goldman Sachs (GS), consensus $3.44; du Pont (DD), consensus $1.59; Morgan Stanley (MS), consensus 60c; Danaher (DHR), consensus 80c; BlackRock (BLK), consensus $4.14; Blackstone (BX), consensus 55c; Chipotle Mexican Grill (CMG), consensus $2.86; Mattel (MAT), consensus 9c; Snap-on (SNA), consensus $1.54; AutoNation (AN), consensus 74c.
06:20 EDTBXTelefonica, Blackstone to form Axonix mobile-advertising venture, WSJ reports
Subscribe for More Information
April 15, 2014
11:33 EDTBXBlackstone volatility increases into Q1
Subscribe for More Information
April 14, 2014
08:31 EDTBXBlackstone and Goldman Sachs to acquire Ipreo from KKR
Subscribe for More Information
07:20 EDTBXKKR to sell Ipreo to Blackstone, Goldman Sachs for $975M, Financial Times says
Subscribe for More Information
April 10, 2014
11:23 EDTCVSRite Aid hits 52-week high after results, sales view top estimates
Shares of retail drugstore Rite Aid (RAD) are rallying after the company's fourth quarter results and fiscal 2015 revenue outlook topped analysts' consensus estimates. WHAT'S NEW: This morning, Rite Aid reported fourth quarter adjusted earnings per share of 10c and revenue of $6.6B, compared to expectations of 4c and $6.54B, respectively. Q4 same store sales increased 2.1%. Rite Aid forecast FY15 EPS of 31c-42c, compared to the consensus of 35c. FY15 revenue was seen at $26B-$26.5B, ahead of the consensus $25.75B. FY15 same-store sales are expected by the company to be up 2.5%-4.5%. WHAT'S NOTABLE: Rite Aid also announced it has acquired RediClinic, which currently operates 30 clinics in the greater Houston, Austin and San Antonio areas. Rite Aid CEO John Standley said, “Our recent acquisitions of Health Dialog and RediClinic, our expanded partnership with McKesson and our continued commitment to investing in our store base have positioned us to transition our strategy from turnaround to growth as we more aggressively pursue opportunities to become a growing retail healthcare company.” PRICE ACTION: In late morning trading, Rite Aid rose 71c, or about 11%, to $7.11 on more than twice its average daily trading volume. Earlier in the session, the stock hit a fresh 52-week high of $7.39. Including today's advance, the stock is up approximately 300% over the past twelve months. OTHERS TO WATCH: Other retail drugstore operators include Walgreen Company (WAG) and CVS Caremark (CVS).
11:23 EDTBXOptions with increasing implied volatility: CYTK BX
Subscribe for More Information
09:16 EDTBXRentech announces $150M investment from Blackstone's GSO Capital
Rentech (RTK) announced that GSO Capital Partners LP, the credit investment arm of Blackstone (BX), will invest $150M in Rentech in the form of $100M of convertible preferred stock and a $50M term loan. The transactions closed on April 9. In connection with this investment, Blackstone/GSO appointed two members to Rentech’s Board of Directors: Douglas Ostrover, a senior managing director of Blackstone and co-founder of GSO Capital Partners, and Patrick Moore, the former chairman and chief executive officer of Smurfit-Stone Container Corporation, a paper-based packaging company with significant wood fibre operations. Rentech also announced a settlement with Concerned Rentech Shareholders, whereby CRS will approve an additional member to join Rentech’s Board of Directors and the board’s newly formed Finance Committee. Proceeds from Blackstone/GSO’s investment will fund identified growth opportunities in Rentech’s wood fibre processing business. Rentech also announced changes to its Board of Directors today: Douglas Ostrover, senior managing director of Blackstone and co-founder of GSO Capital Partners, has joined the board. Mr. Ostrover brings shareholder representation and significant finance experience. He has personally overseen GSO’s deployment of $65 billion of capital. Mr. Ostrover will be the chairman of the board’s Finance Committee. Blackstone/GSO appointed Patrick J. Moore, former chairman and chief executive officer of Smurfit-Stone Container Corporation, to the board.
09:06 EDTBXBlackstone reaches a financial closing for Ventika
Fisterra Energy, a company majority owned by funds managed by Blackstone (BX), and Blackstone Energy Partners, announced it has reached a financial closing for Ventika. Ventika will be located in the northeastern Mexican state of Nuevo Leon and is comprised of two 126 megawatt wind farms with total capacity of 252MW. Once completed the project will alleviate significant demands on Mexico’s existing power infrastructure, helping Mexico reduce pollution and CO2 emissions, and meet its target of achieving 35% renewable generation by 2025. The $650M project is being jointly developed by CEMEX (CX) and Fisterra Energy. This investment funds the installation of 84 Acciona AW-3000 wind turbine generators, each with a hub height of 120 meters and a nominal output of 3MW per turbine. Construction of the project, which is scheduled to be completed in FY16, is expected to generate approximately 1K jobs and more than 2K additional jobs in related industries.
07:49 EDTBXApollo, EQT, Blackstone mull offers for Gas Natural unit, Bloomberg says
Subscribe for More Information
April 9, 2014
05:48 EDTBXStocks with implied volatility movement; DLLR BX
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use